Cora Schlesinger
Growth, contrarian, long only

GTX Inc.: The Company's Next Moves

What GTx Has achieved So Far…

GTx Inc. (NASDAQ:GTXI) is a Memphis, Tennessee-based, microcap biopharmaceutical company with a pipeline of small molecule, synthetic, hormone-like drugs to treat cancer, chemotherapy side effects, or provide cancer supportive care. Designation as a "small molecule" drug indicates a traditional big pharma discovery process and chemical structure, as opposed to the biologic drugs. The purpose of this article is to recap GTx's recent progress in furthering development of its lead drug candidate, enobosarm (GTX-024, formerly Ostarine). This report is longer than I prefer for my writing style, but a lot of good things have happened of late. As a "soft" positive, CEO Dr. Mitch Steiner had the honor of giving a one-hour seminar...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details